SQZ - SQZ Biotechnologies GAAP EPS of -$0.78 misses by $0.01 revenue of $3.22M misses by $0.97M

• SQZ Biotechnologies press release ( NYSE: SQZ ): Q2 GAAP EPS of -$0.78 misses by $0.01 .
• Revenue of $3.22M (-29.1% Y/Y) misses by $0.97M .

• “We are excited by meaningful progress in our clinical trials and also the receipt of FDA Fast Track Designation for our APC clinical candidate across HPV16+ tumors,” said Armon Sharei, Ph.D., CEO and Founder at SQZ Biotechnologies. “We also highlighted the progress in developing our Point-of-Care manufacturing system which supports our long-term vision to enable broad accessibility of cell therapies. Finally, I am delighted by the addition of our newest senior team member, Dr. Marshelle Smith Warren as our Chief Medical Officer, and the elevation of Micah Zajic to Chief Financial Officer.”

For further details see: